← All trials
NCT05391360
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 11, 2021
- Primary completion
- Jul 11, 2023
- Completion date
- Jul 11, 2023
- First posted
- May 25, 2022
- Last posted
- May 25, 2022
- Enrollment
- 128
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sunshine Lake Pharma Co., Ltd.Lead sponsor
- Southern Medical UniversityOverall official - principal investigator
- Jinlin UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.